Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality

[1]  Sripriya Ravindra Kumar,et al.  Systemic AAV vectors for widespread and targeted gene delivery in rodents , 2019, Nature Protocols.

[2]  Fred Wolf,et al.  Ultrafast optogenetic stimulation of the auditory pathway by targeting‐optimized Chronos , 2018, The EMBO journal.

[3]  K. D. Karavitaki,et al.  Gene Transfer with AAV9-PHP.B Rescues Hearing in a Mouse Model of Usher Syndrome 3A and Transduces Hair Cells in a Non-human Primate , 2018, Molecular therapy. Methods & clinical development.

[4]  D. Dalkara,et al.  Dosage Thresholds and Influence of Transgene Cassette in Adeno-Associated Virus-Related Toxicity. , 2018, Human gene therapy.

[5]  J. Forrester,et al.  CNS infection and immune privilege , 2018, Nature Reviews Neuroscience.

[6]  B. Davidson,et al.  Lysosomal storage diseases , 2018, Nature Reviews Disease Primers.

[7]  P. Sieving,et al.  Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Joan W. Miller,et al.  Breaking and Sealing Barriers in Retinal Gene Therapy. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  B. Ravina,et al.  Gene therapy for neurological disorders: progress and prospects , 2018, Nature Reviews Drug Discovery.

[10]  A. Auricchio,et al.  Seeing the Light after 25 Years of Retinal Gene Therapy. , 2018, Trends in molecular medicine.

[11]  B. Hyman,et al.  Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65 , 2018, Molecular therapy. Methods & clinical development.

[12]  T. Moser,et al.  Optogenetic stimulation of cochlear neurons activates the auditory pathway and restores auditory-driven behavior in deaf adult gerbils , 2018, Science Translational Medicine.

[13]  P. Avan,et al.  Clarin-1 gene transfer rescues auditory synaptopathy in model of Usher syndrome , 2018, The Journal of clinical investigation.

[14]  N. Boulis,et al.  Progress in gene and cell therapies for the neuronal ceroid lipofuscinoses , 2018, Expert opinion on biological therapy.

[15]  M. Tuszynski,et al.  Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial , 2018, JAMA neurology.

[16]  James E. DiCarlo,et al.  Gene therapy and genome surgery in the retina , 2018, The Journal of clinical investigation.

[17]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[18]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2018 , 2018, Alzheimer's & dementia.

[19]  I. Alexander,et al.  Gene therapy clinical trials worldwide to 2017: An update , 2018, The journal of gene medicine.

[20]  Yun-peng Liu,et al.  LncRNA H19 contributes to hippocampal glial cell activation via JAK/STAT signaling in a rat model of temporal lobe epilepsy , 2018, Journal of Neuroinflammation.

[21]  S. S. St Martin,et al.  Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Qiang Wang,et al.  The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  G. Petsko,et al.  AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. , 2018, Human gene therapy. Clinical development.

[24]  N. Boulis,et al.  AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials , 2018, Expert opinion on biological therapy.

[25]  HindererChristian,et al.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN , 2018 .

[26]  Richard J. H. Smith,et al.  Enhanced viral-mediated cochlear gene delivery in adult mice by combining canal fenestration with round window membrane inoculation , 2018, Scientific Reports.

[27]  B. Burton,et al.  Update on phase 1/2 clinical trials for MPS I and MPS II using ZFN-mediated in vivo genome editing , 2018 .

[28]  Sruthi Mantri,et al.  Identification of preexisting adaptive immunity to Cas9 proteins in humans , 2018, Nature Medicine.

[29]  J. Sagen,et al.  Experimental Gene Therapy with Serine-Histogranin and Endomorphin 1 for the Treatment of Chronic Neuropathic Pain , 2017, Front. Mol. Neurosci..

[30]  B. Wilhelm,et al.  AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  Chunxing Yang,et al.  Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS , 2017, Neuroscience.

[32]  B. Byrne,et al.  Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. , 2017, The Lancet. Child & adolescent health.

[33]  C. J. Lee,et al.  AAV-Mediated Astrocyte-Specific Gene Expression under Human ALDH1L1 Promoter in Mouse Thalamus , 2017, Experimental neurobiology.

[34]  L. Vandenberghe,et al.  Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction. , 2017, Human gene therapy.

[35]  Hildegard Büning,et al.  Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution. , 2017, Human gene therapy.

[36]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[37]  F. Mingozzi,et al.  Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial , 2017, Human gene therapy.

[38]  J. Rinholm,et al.  Visualization and Live Imaging of Oligodendrocyte Organelles in Organotypic Brain Slices Using Adeno-associated Virus and Confocal Microscopy. , 2017, Journal of visualized experiments : JoVE.

[39]  David A. Williams,et al.  Hematopoietic Stem‐Cell Gene Therapy for Cerebral Adrenoleukodystrophy , 2017, The New England journal of medicine.

[40]  F. Jamme,et al.  Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease , 2017, Acta neuropathologica communications.

[41]  A. Ferry,et al.  A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[43]  Ru Xiao,et al.  Single stranded adeno-associated virus achieves efficient gene transfer to anterior segment in the mouse eye , 2017, PloS one.

[44]  P. Grandi,et al.  Viral vectors for therapy of neurologic diseases , 2017, Neuropharmacology.

[45]  W. Low,et al.  Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I. , 2017, Human gene therapy.

[46]  W. Hauswirth,et al.  Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS , 2017, Molecular therapy. Nucleic acids.

[47]  Claus V. Hallwirth,et al.  Identification of liver-specific enhancer–promoter activity in the 3′ untranslated region of the wild-type AAV2 genome , 2017, Nature Genetics.

[48]  J. Moffett,et al.  Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease , 2017, Front. Mol. Neurosci..

[49]  J. Carette,et al.  Host determinants of adeno-associated viral vector entry. , 2017, Current opinion in virology.

[50]  M. Agbandje-McKenna,et al.  Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion , 2017, Proceedings of the National Academy of Sciences.

[51]  C. Ciron,et al.  Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders , 2017, Gene Therapy.

[52]  S. Kügler,et al.  A MicroRNA124 Target Sequence Restores Astrocyte Specificity of gfaABC1D-Driven Transgene Expression in AAV-Mediated Gene Transfer , 2017, Molecular therapy. Nucleic acids.

[53]  V. Sheffield,et al.  Gene Therapeutic Reversal of Peripheral Olfactory Impairment in Bardet-Biedl Syndrome. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  SrivastavaArun,et al.  AAV Infection: Protection from Cancer. , 2017 .

[55]  R. Chandler,et al.  Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models. , 2017, Human gene therapy.

[56]  L. Vandenberghe,et al.  Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection , 2017, Scientific Reports.

[57]  A. Griffith,et al.  Gene Therapy Restores Balance and Auditory Functions in a Mouse Model of Usher Syndrome. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  M. Klugmann,et al.  Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model , 2017, Brain : a journal of neurology.

[59]  D. Corey,et al.  Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  J. R. Holt,et al.  Gene Therapy Restores Auditory and Vestibular Function in a Mouse Model of Usher Syndrome Type 1c , 2017, Nature Biotechnology.

[61]  J. R. Holt,et al.  A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear , 2017, Nature Biotechnology.

[62]  Brian Zingg,et al.  AAV-Mediated Anterograde Transsynaptic Tagging: Mapping Corticocollicular Input-Defined Neural Pathways for Defense Behaviors , 2017, Neuron.

[63]  Yoshiyuki Yamazaki,et al.  Improved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  B. Hyman,et al.  Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 , 2016, Molecular therapy. Methods & clinical development.

[65]  L. Pereira de Almeida,et al.  Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[66]  Benjamin E. Deverman,et al.  Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B , 2016, Front. Mol. Neurosci..

[67]  E. Bongarzone,et al.  Intrathecal administration of AAV/GALC vectors in 10–11‐day‐old twitcher mice improves survival and is enhanced by bone marrow transplant , 2016, Journal of neuroscience research.

[68]  HindererChristian,et al.  Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. , 2016 .

[69]  Laetitia van Wittenberghe,et al.  Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy , 2016, Molecular therapy. Methods & clinical development.

[70]  Douglas R Martin,et al.  In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  J. Bennett,et al.  In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. , 2016, Human molecular genetics.

[72]  Samantha Parker,et al.  Adeno-Associated Virus-Based Gene Therapy for CNS Diseases , 2016, Human gene therapy.

[73]  J. Prieto,et al.  Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  J. R. Holt,et al.  RNA Interference Prevents Autosomal-Dominant Hearing Loss , 2016, American journal of human genetics.

[75]  T. Golde,et al.  Microglia-specific targeting by novel capsid-modified AAV6 vectors , 2016, Molecular therapy. Methods & clinical development.

[76]  Sourav R. Choudhury,et al.  Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  Mario Renda,et al.  Rhodopsin targeted transcriptional silencing by DNA-binding , 2016, eLife.

[78]  Peng Liu,et al.  Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder , 2016, Scientific Reports.

[79]  B. Hyman,et al.  Exosome-associated AAV vector as a robust and convenient neuroscience tool , 2016, Gene Therapy.

[80]  Jessica Zucman-Rossi,et al.  Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma , 2016, Molecular & cellular oncology.

[81]  Sripriya Ravindra Kumar,et al.  Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain , 2015, Nature Biotechnology.

[82]  P. Gregory,et al.  Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors , 2015, Nature Biotechnology.

[83]  C. Vite,et al.  Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  Jessica Zucman-Rossi,et al.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas , 2015, Nature Genetics.

[85]  T. Shimada,et al.  Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector , 2015, Scientific Reports.

[86]  Ru Xiao,et al.  In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. , 2015, Cell reports.

[87]  S. Shaffer,et al.  Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan. , 2015, Human molecular genetics.

[88]  T. Yamamori,et al.  Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex , 2015, Neuroscience Research.

[89]  H. J. Baker,et al.  AAV-Mediated Gene Delivery in a Feline Model of Sandhoff Disease Corrects Lysosomal Storage in the Central Nervous System , 2015, ASN neuro.

[90]  R. Samulski,et al.  Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. , 2015, Human gene therapy.

[91]  M. Souweidane,et al.  Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. , 2015, Human gene therapy. Clinical development.

[92]  David Hurlbut,et al.  Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  J. Mendell,et al.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[94]  A. Elkahloun,et al.  Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. , 2015, The Journal of clinical investigation.

[95]  P. Aebischer,et al.  SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice , 2015, Annals of clinical and translational neurology.

[96]  Y. Tao,et al.  Current gene therapy using viral vectors for chronic pain , 2015, Molecular pain.

[97]  H. J. Baker,et al.  Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease , 2014, Gene Therapy.

[98]  Dominik Niopek,et al.  CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. , 2014, Biotechnology journal.

[99]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[100]  A. Fleisher,et al.  A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[101]  W. Chung,et al.  Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.

[102]  M. Kubota,et al.  Canavan disease: Clinical features and recent advances in research , 2014, Pediatrics international : official journal of the Japan Pediatric Society.

[103]  O. Isacson,et al.  Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection , 2014, Neuroscience Letters.

[104]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[105]  R. Desrosiers,et al.  Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[106]  J. R. Holt,et al.  Sound Strategies for Hearing Restoration , 2014, Science.

[107]  Michael J. Castle,et al.  Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport. , 2014, Human gene therapy.

[108]  R. L. Clark,et al.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  M. Kay,et al.  Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[110]  K. Flanigan,et al.  Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. , 2014, Human gene therapy. Clinical development.

[111]  B. Hyman,et al.  Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain , 2013, Science Translational Medicine.

[112]  Krystof S. Bankiewicz,et al.  ADENO-ASSOCIATED VIRUS TYPE 6 IS RETROGRADELY TRANSPORTED IN THE NON-HUMAN PRIMATE BRAIN , 2013, Gene Therapy.

[113]  S. Tsuji,et al.  Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons , 2013, EMBO molecular medicine.

[114]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[115]  E. Ayuso,et al.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. , 2013, The Journal of clinical investigation.

[116]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[117]  D. Borchelt,et al.  Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain , 2013, PloS one.

[118]  Deniz Dalkara,et al.  In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous , 2013, Science Translational Medicine.

[119]  A. Benraiss,et al.  Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. , 2013, Cell stem cell.

[120]  F. Bushman,et al.  Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. , 2013, Human gene therapy.

[121]  P. Aebischer,et al.  Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. , 2013, Human gene therapy.

[122]  M. Staufenbiel,et al.  Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice , 2013, Scientific Reports.

[123]  R. Carcenac,et al.  Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[124]  J. Stein‐Streilein.  Mechanisms of Immune Privilege in the Posterior Eye , 2013, International reviews of immunology.

[125]  D. Shera,et al.  Long-Term Follow-Up After Gene Therapy for Canavan Disease , 2012, Science Translational Medicine.

[126]  R. Samulski,et al.  Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.

[127]  J. R. Holt,et al.  Gene therapy for deaf mice goes viral. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[128]  K. Purpura,et al.  Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. , 2012, Human gene therapy methods.

[129]  R. Edwards,et al.  Restoration of Hearing in the VGLUT3 Knockout Mouse Using Virally Mediated Gene Therapy , 2012, Neuron.

[130]  Pei-Rong Wang,et al.  Induction of hepatocellular carcinoma by in vivo gene targeting , 2012, Proceedings of the National Academy of Sciences.

[131]  B. Byrne,et al.  Gene Therapy for Aromatic l-Amino Acid Decarboxylase Deficiency , 2012, Science Translational Medicine.

[132]  W. Low,et al.  Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. , 2012, Molecular genetics and metabolism.

[133]  M. Choolani,et al.  Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems , 2012, Gene Therapy.

[134]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[135]  B. Davidson,et al.  Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[136]  L. Vandenberghe,et al.  Novel adeno-associated viral vectors for retinal gene therapy , 2011, Gene Therapy.

[137]  C. Mueller,et al.  Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[138]  E. Surace,et al.  MicroRNA-Restricted Transgene Expression in the Retina , 2011, PloS one.

[139]  P. Boekstegers,et al.  Cardiac AAV9-S100A1 Gene Therapy Rescues Post-Ischemic Heart Failure in a Preclinical Large Animal Model , 2011, Science Translational Medicine.

[140]  W. Low,et al.  Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I , 2011, Neurobiology of Disease.

[141]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[142]  J. Babb,et al.  Longitudinal Whole-Brain N-Acetylaspartate Concentration in Healthy Adults , 2011, American Journal of Neuroradiology.

[143]  S. Ojeda,et al.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[144]  Hojun Li,et al.  Assessing the potential for AAV vector genotoxicity in a murine model. , 2011, Blood.

[145]  W. Hauswirth,et al.  Ab-Externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter , 2011, PloS one.

[146]  S. Raoul,et al.  Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[147]  G. Veres,et al.  Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[148]  H. Fu,et al.  Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[149]  Ivana K. Kim,et al.  Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[150]  E. Mufson,et al.  Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains , 2011, Movement disorders : official journal of the Movement Disorder Society.

[151]  T. Golde,et al.  Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain , 2010, Journal of Neuroscience Methods.

[152]  R. Klein,et al.  Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[153]  J. Jankovic,et al.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial , 2010, The Lancet Neurology.

[154]  Erik Sahai,et al.  Deficits in axonal transport precede ALS symptoms in vivo , 2010, Proceedings of the National Academy of Sciences.

[155]  P. Pivirotto,et al.  Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[156]  J. Golden,et al.  Safety and Efficacy of Subretinal Readministration of a Viral Vector in Large Animals to Treat Congenital Blindness , 2010, Science Translational Medicine.

[157]  M. Rich,et al.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2010, Nature Biotechnology.

[158]  W. Jagust,et al.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease , 2009, Neurology.

[159]  E. Huang,et al.  Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. , 2009, Human gene therapy.

[160]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[161]  Krystof S. Bankiewicz,et al.  Real-time MR imaging of adeno-associated viral vector delivery to the primate brain , 2009, NeuroImage.

[162]  J. Muenzer,et al.  Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice , 2009, Gene Therapy.

[163]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[164]  P. Pivirotto,et al.  Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. , 2009, Human gene therapy.

[165]  A. Cressant,et al.  Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. , 2009, Human gene therapy.

[166]  J. Wilson,et al.  Tailoring the AAV vector capsid for gene therapy , 2009, Gene Therapy.

[167]  R. Bartus,et al.  Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS , 2009, Neurobiology of Disease.

[168]  Steve Iliffe,et al.  Alzheimer’s disease , 2009, BMJ : British Medical Journal.

[169]  D. Mccarty.  Self-complementary AAV vectors; advances and applications. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[170]  Anne R. Pariser,et al.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment , 2008, Nature Biotechnology.

[171]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[172]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[173]  J. L. Eberling,et al.  Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.

[174]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.

[175]  James M. Wilson,et al.  AAV as an immunogen. , 2007, Current gene therapy.

[176]  J. Wolfe,et al.  A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic Disease , 2007, The Journal of Neuroscience.

[177]  Daniel G. Miller,et al.  AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.

[178]  J. Kordower,et al.  AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease , 2007, Neurobiology of Disease.

[179]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[180]  M. Tuszynski,et al.  Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys , 2007, Movement disorders : official journal of the Movement Disorder Society.

[181]  Marcela V Maus,et al.  CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[182]  R. Bakay,et al.  Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.

[183]  T. Golde,et al.  Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid β, Amyloid β40, and Amyloid β42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice , 2006, The Journal of Neuroscience.

[184]  B. Melchior,et al.  CNS immune privilege: hiding in plain sight , 2006, Immunological reviews.

[185]  P. Pivirotto,et al.  Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[186]  A Freese,et al.  Natural History of Canavan Disease Revealed by Proton Magnetic Resonance Spectroscopy (1H‐MRS) and Diffusion-weighted MRI , 2006, Neuropediatrics.

[187]  J. Bringas,et al.  Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. , 2006, Human gene therapy.

[188]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[189]  Philip R. Johnson,et al.  Characterization of Adeno-Associated Virus Genomes Isolated from Human Tissues , 2005, Journal of Virology.

[190]  I. Martins,et al.  Functional Correction of CNS Phenotypes in a Lysosomal Storage Disease Model Using Adeno-Associated Virus Type 4 Vectors , 2005, The Journal of Neuroscience.

[191]  Lili Wang,et al.  No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[192]  James M. Wilson,et al.  New recombinant serotypes of AAV vectors. , 2005, Current gene therapy.

[193]  T. Serikawa,et al.  Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. , 2005, Brain research. Molecular brain research.

[194]  J. Glass,et al.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man , 2004, Experimental Neurology.

[195]  M. During,et al.  Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery , 2003, Neurobiology of Disease.

[196]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[197]  C. Vite,et al.  Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Correction of Storage Lesions in the Brains of β-Glucuronidase-Deficient Mice , 2003, Journal of Virology.

[198]  R. Mandel,et al.  Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[199]  M. R. Delgado Alvira,et al.  Adeno-associated viruses undergo substantial evolution in primates during natural infections , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[200]  H. Mizukami,et al.  Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis , 2002, The Journal of Neuroscience.

[201]  D. Shera,et al.  Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. , 2002, Human gene therapy.

[202]  R. Kotin,et al.  Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[203]  G. Kobinger,et al.  Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. , 2001, Human molecular genetics.

[204]  R. Sánchez-Pernaute,et al.  Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[205]  M. During,et al.  Combined injection of rAAV with mannitol enhances gene expression in the rat brain. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[206]  William Jagust,et al.  Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.

[207]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[208]  A. Hottinger,et al.  Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. , 2000, Human molecular genetics.

[209]  Prerna Sharma,et al.  Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.

[210]  E. Terwilliger,et al.  Adeno-Associated Virus Vector-Mediated Transgene Integration into Neurons and Other Nondividing Cell Targets , 1998, Journal of Virology.

[211]  J. Milbrandt,et al.  Neurturin, a relative of glial-cell-line-derived neurotrophic factor , 1996, Nature.

[212]  M. Weitzman,et al.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis , 1996, Journal of virology.

[213]  B. Hyman,et al.  Frequency of the apolipoprotein E ε2 allele is diminished in sporadic Alzheimer disease , 1994, Neuroscience Letters.

[214]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[215]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[216]  T. Friedmann.  A brief history of gene therapy , 1992, Nature Genetics.

[217]  A. Miller,et al.  Human gene therapy comes of age , 1992, Nature.

[218]  S. Michel,et al.  Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease , 1992, Human Genetics.

[219]  Lynne,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[220]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[221]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[222]  P. D. Lewis,et al.  A QUANTITATIVE STUDY OF CELL PROLIFERATION IN EPENDYMA AND CHOROID PLEXUS IN THE POSTNATAL RAT BRAIN , 1979, Neuropathology and applied neurobiology.

[223]  C. Vite,et al.  Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. , 2018, Human gene therapy.

[224]  A. Srivastava,et al.  AAV Infection: Protection from Cancer. , 2017, Human gene therapy.

[225]  Michael J. Castle,et al.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. , 2016, Methods in molecular biology.

[226]  D. Grimm,et al.  Pluribus Unum : Fifty years of research , millions of viruses , and one goal-tailored acceleration of AAV evolution , 2015 .

[227]  A. Ballabio,et al.  Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. , 2014, Human gene therapy.

[228]  Y. Chien,et al.  AADC deficiency: occurring in humans, modeled in rodents. , 2013, Advances in pharmacology.

[229]  P Aebischer,et al.  Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6 , 2010, Gene Therapy.

[230]  D. Duan,et al.  Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[231]  H. Nakai,et al.  Characterization of genome integrity for oversized recombinant AAV vector. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[232]  I. Bièche,et al.  Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. , 2010, Human molecular genetics.

[233]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[234]  H. Mizukami,et al.  A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[235]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[236]  M. Tuszynski,et al.  Efficient Retrograde Neuronal Transduction Utilizing Self-complementary AAV1. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[237]  T. Seyfried,et al.  Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[238]  A. Roses,et al.  Apolipoprotein E and Alzheimer's disease. , 1996, Annual review of neuroscience.

[239]  Fulvio Mavilio,et al.  Gene therapy , 1993, Nature.

[240]  M. Rocchi,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[241]  H. Tallan.  Studies on the distribution of N-acetyl-L-aspartic acid in brain. , 1957, The Journal of biological chemistry.